Johnson & Johnson Stock Ticks Lower Amid Valuation Debate

Johnson & Johnson stock has pulled back slightly after strong guidance and valuation debate. As of September 18, 2026, shares traded around USD 269.97 on the New York Stock Exchange, down 0.09% on the day.

The healthcare group's 2026 earnings outlook remains robust, with a raised consensus estimate for earnings per share increasing from USD 11.59 to USD 11.61 over the past 30 days. This has contributed to the company's stock price appreciation of 18.3% over the past three months and 30.6% since the start of 2026.

Despite legal and patent headwinds, valuation metrics show that Johnson & Johnson is still priced as a premium healthcare name, with a price-to-earnings ratio of 31.28 and a PEG ratio of 2.55. The company's Innovative Medicine segment and new therapies in development continue to support growth expectations.